Marker Therapeutics
NASDAQ: MRKRHouston, US · Founded 2018 · Delaware corporation · 22 employees on LinkedIn · 2 known investors
Marker Therapeutics develops novel T cell therapies, including adoptive T cell therapy approaches, for clinical applications in oncology and other diseases with high unmet need. The company focuses on advancing cell therapy candidates from research through clinical development.
Founders & leadership
Marker Therapeutics was founded in 2018 by Juan Vera and Dr. Vera.
JV
Juan VeraCo-founder
DV
Dr. VeraCo-founder
GW
Glynn WilsonExecutive
JB
John BonfiglioExecutive
Board
SE
JW
John WilsonBoard director
KK
Katharine KnobilBoard director
DE
David EansorBoard director
MR
Mark ReddishBoard director
DL
David Laskow-PooleyBoard director
SG
Sherry GrisewoodBoard director
FW
Frederick WassermanBoard director
Investors · 2
Reported raises · per SEC filings
Form D private placements$28.5M disclosed across 4 of 5 rounds · 2016–2024
▶$16.1MraisedDec 2024 · 5 investors · BiotechnologyRule 506(b)
▶$16.1MraisedDec 2024 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Juan VeraExecutive Officer, Director
- Steven ElmsDirector
- John WilsonDirector
- Katharine KnobilDirector
- David EansorDirector
- Offering amount
- $16.1M
- Amount sold
- $16.1M
- Minimum investment
- $100K
- Sales commissions
- $816K
- Placement agents
- Brookline Capital Markets, a division of Arcadia Securities, LLC, CANACCORD GENUITY LLC
- First sale
- Dec 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3.1MraisedMay 2018 · 1 investors · BiotechnologyRule 506(b)
▶$3.1MraisedMay 2018 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Mark ReddishDirector
- Glynn WilsonDirector
- Michael LoiaconoExecutive Officer
- Peter HoangExecutive Officer, Director
- Sherry GrisewoodDirector
- Frederick WassermanDirector
- David Laskow-PooleyDirector
- Offering amount
- $3.1M
- Amount sold
- $3.1M
- First sale
- May 2018
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$6.2MraisedJun 2017 · 87 investors · BiotechnologyRule 506(b)
▶$6.2MraisedJun 2017 · 87 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Mark ReddishDirector
- Sherry GrisewoodDirector
- Michael J. LoiaconoExecutive Officer
- Frederick WassermanDirector
- David Laskow-PooleyDirector
- Joshua SilvermanDirector
- Glynn WilsonExecutive Officer, Director
- Offering amount
- $6.2M
- Amount sold
- $6.2M
- Minimum investment
- $7K
- Sales commissions
- $619K
- Placement agents
- American Portfolios Financial Services, Inc., Katalyst Securities LLC
- First sale
- Jun 2017
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$3.1MraisedSep 2016 · 46 investors · BiotechnologyRule 506(b)
▶$3.1MraisedSep 2016 · 46 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- SHERRY GRISEWOODDirector
- JOHN BONFIGLIOExecutive Officer, Director
- MARK REDDISHDirector
- FREDERICK WASSERMANDirector
- GLYNN WILSONExecutive Officer, Director
- DAVID LASKOW-POOLEYDirector
- MICHAEL J LOIACONOExecutive Officer
- Offering amount
- $5M
- Amount sold
- $3.1M
- Sales commissions
- $313.5K
- Placement agents
- WEST PARK CAPITAL INC., KATALYST SECURITIES LLC
- First sale
- Aug 2016
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶Undisclosed amountofferedAug 2016 · 11 investors · BiotechnologyRule 506(b)
▶Undisclosed amountofferedAug 2016 · 11 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Mark ReddishDirector
- Glynn WilsonExecutive Officer, Director
- David Laskow-PooleyDirector
- Sherry GrisewoodDirector
- John BonfiglioExecutive Officer, Director
- Frederick WassermanDirector
- Sales commissions
- $245K
- Placement agents
- GP Nuremenkari Inc.
- First sale
- Aug 2016
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlap
Robinhood21 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Seeking Alpha21 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
TradingView20 shared keywordsTradingView is a charting platform and social network used by over 100 million traders and investors worldwide to analyze and trade across global financial markets. The platform provides tools for technical analysis, market data, and community collaboration for retail and institutional traders.
TipRanks18 shared keywordsFinancial analysis and stock research platform.
Companies competing with Marker Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2023 | $664.8K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Marker Therapeutics do?
- Marker Therapeutics develops novel T cell therapies, including adoptive T cell therapy approaches, for clinical applications in oncology and other diseases with high unmet need. The company focuses on advancing cell therapy candidates from research through clinical development.
- Who founded Marker Therapeutics?
- Marker Therapeutics was founded by Juan Vera, Dr. Vera in 2018.
- Who are Marker Therapeutics's investors?
- Marker Therapeutics's investors include Aisling Capital, New Enterprise Associates (NEA).
- How much funding has Marker Therapeutics raised?
- Marker Therapeutics has disclosed $28.5M raised across 4 of its 5 known rounds.
- Where is Marker Therapeutics headquartered?
- Marker Therapeutics is headquartered in Houston, US.